rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RZLT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Wedbush raises Rezolute stock price target on tumor trial data
      Nov 17Investing.comRZLT
      Rezolute Raises $100 Million, Advances Ersodetug Toward Commercialization
      Nov 13BenzingaRZLT
      Rezolute Reports Phase 3 upLIFT Study Meets Primary Efficacy Endpoint in Tumor Hyperinsulinism
      Nov 13Yahoo FinanceRZLT
      Why is Rezolute stock surging today?
      Nov 13Investing.comRZLT
      Rezolute stock rises on positive Phase 3 upLIFT trial results
      Nov 13Investing.comRZLT
      Rezolute stock holds Buy rating at H.C. Wainwright on trial progress
      Oct 15Investing.comRZLT
      Citizens reiterates Market Outperform on Rezolute stock on trial data
      Oct 15Investing.comRZLT
      Rezolute completes enrollment in phase 3 tumor study
      Oct 14Investing.comRZLT
      Rezolute upgraded at Cantor on pre-BLA meeting for ersodetug

      Cantor Fitzgerald upgrades Rezolute as FDA signals ersodetug congenital hyperinsulinism data is sufficient for a filing. Read more here.

      Oct 6Seeking AlphaRZLT
      H.C. Wainwright reiterates Buy on Rezolute stock, $10 target
      Oct 6Investing.comRZLT
      Citizens raises Rezolute stock price target on FDA feedback
      Oct 6Investing.comRZLT
      Cantor Fitzgerald Upgrades Rezolute to Overweight From Neutral
      Oct 6Yahoo FinanceRZLT
      FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints - Rezolut

      Rezolute (NASDAQ: RZLT) shares surged after the FDA recommended a pre-BLA meeting for its congenital hyperinsulinism drug, ersodetug.

      Oct 5BenzingaRZLT
      Rezolute receives FDA recommendation for pre-BLA meeting on ersodetug
      Oct 5Investing.comRZLT
      Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment

      Rezolute (RZLT) said Monday that the US Food and Drug Administration has recommended a meeting befor

      Oct 5Yahoo FinanceRZLT
      Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’
      Oct 5Yahoo FinanceRZLT
      Rezolute stock rating upgraded to Buy at Craig-Hallum on trial data
      Sep 29Investing.comRZLT
      Craig-Hallum Upgrades Rezolute to Buy From Hold, Price Target is $7
      Sep 29Yahoo FinanceRZLT
      H.C. Wainwright raises Rezolute stock price target on trial data
      Sep 28Investing.comRZLT
      Citizens reiterates Rezolute stock rating on tumor trial results due
      Sep 25Investing.comRZLT
      Rezolute Fiscal Q4 Loss Narrows
      Sep 24Yahoo FinanceRZLT
      Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset
      Sep 10Seeking AlphaRZLT
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailRZLTPLX
      Rezolute drops on regulatory update on lead asset (RZLT:NASDAQ)
      Sep 9Seeking AlphaRZLT
      Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint

      Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regulatory path unresolved and without a specific timeline for agency feedback. Key Investor TakeawaysThe FDA review remains ongoing as the agency evaluates whether there is a potential regulatory path forward for ersodetug in congenital hyperinsulinism.

      Sep 9Yahoo FinanceRZLT
      Rezolute awaits FDA feedback on congenital HI treatment data
      Sep 9Investing.comRZLT

      This is the newest page. Registered accounts read further back.